Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898108227> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2898108227 endingPage "S903" @default.
- W2898108227 startingPage "S902" @default.
- W2898108227 abstract "Previous trial data have documented the efficacy of first-line bevacizumab-based regimens, including bevacizumab-pemetrexed combinations in advanced non-small cell lung cancer (NSCLC). We herein aimed to further assess the safety and efficacy of pemetrexed monotherapy versus bevacizumab-containing or other chemotherapy regimens in a real-world NSCLC population. The medical records of 753 patients with advanced-stage non-squamous NSCLC, treated with bevacizumab-based regimens, pemetrexed monotherapy, or other treatments, as first-line therapy, were retrospectively reviewed and analyzed for efficacy and safety endpoints. The bevacizumab-based group had the highest percentage of partial response/PR (32.3% vs 22.8% for pemetrexed and 20.0% for other treatments) and a significantly lower incidence of progressive disease/PD (35.92%, 30.17%, and 50.48%, for pemetrexed, bevacizumab-based, and other, respectively; p < 0.0001). Bevacizumab-based regimens achieved a better overall survival (OS) rate (measured at the end of treatment) (pemetrexed 29.6%, bevacizumab-based 35.7%, and other treatments 8.9%; p < 0.0001). However, median OS was not improved (10 months, 12 months, and 13 months for pemetrexed, bevacizumab-based, and other treatments, respectively; p=0.007). A significantly higher incidence of cough (p = 0.001) and hemoptysis (p < 0.0001) in the bevacizumab-based arm, pain in the pemetrexed arm (p = 0.007), and alopecia in the other treatments arm (p < 0.0001) was observed during treatment. A significantly higher incidence of hemoptysis in the bevacizumab-based arm (p < 0.0001) and alopecia in the other treatments arm (p < 0.0001) was seen at the end of first-line treatment. Bevacizumab-based regimens resulted in improved treatment response and short-term survival rate, but not in improved OS. An increased, albeit acceptable, toxicity was also observed among bevacizumab-treated patients as compared to those treated with pemetrexed monotherapy." @default.
- W2898108227 created "2018-11-02" @default.
- W2898108227 creator A5003502823 @default.
- W2898108227 creator A5038983218 @default.
- W2898108227 creator A5040324418 @default.
- W2898108227 creator A5046026753 @default.
- W2898108227 creator A5049509860 @default.
- W2898108227 creator A5083015425 @default.
- W2898108227 creator A5090471467 @default.
- W2898108227 date "2018-10-01" @default.
- W2898108227 modified "2023-09-30" @default.
- W2898108227 title "P3.01-94 Safety and Efficacy of First-Line Pemetrexed Versus Bevacizumab-Containing Regimens in Advanced Non-Small Cell Lung Cancer" @default.
- W2898108227 doi "https://doi.org/10.1016/j.jtho.2018.08.1654" @default.
- W2898108227 hasPublicationYear "2018" @default.
- W2898108227 type Work @default.
- W2898108227 sameAs 2898108227 @default.
- W2898108227 citedByCount "0" @default.
- W2898108227 crossrefType "journal-article" @default.
- W2898108227 hasAuthorship W2898108227A5003502823 @default.
- W2898108227 hasAuthorship W2898108227A5038983218 @default.
- W2898108227 hasAuthorship W2898108227A5040324418 @default.
- W2898108227 hasAuthorship W2898108227A5046026753 @default.
- W2898108227 hasAuthorship W2898108227A5049509860 @default.
- W2898108227 hasAuthorship W2898108227A5083015425 @default.
- W2898108227 hasAuthorship W2898108227A5090471467 @default.
- W2898108227 hasBestOaLocation W28981082271 @default.
- W2898108227 hasConcept C120665830 @default.
- W2898108227 hasConcept C121332964 @default.
- W2898108227 hasConcept C126322002 @default.
- W2898108227 hasConcept C141071460 @default.
- W2898108227 hasConcept C143998085 @default.
- W2898108227 hasConcept C2776256026 @default.
- W2898108227 hasConcept C2776694085 @default.
- W2898108227 hasConcept C2777240266 @default.
- W2898108227 hasConcept C2777802072 @default.
- W2898108227 hasConcept C2778239845 @default.
- W2898108227 hasConcept C2908647359 @default.
- W2898108227 hasConcept C61511704 @default.
- W2898108227 hasConcept C71924100 @default.
- W2898108227 hasConcept C90924648 @default.
- W2898108227 hasConcept C99454951 @default.
- W2898108227 hasConceptScore W2898108227C120665830 @default.
- W2898108227 hasConceptScore W2898108227C121332964 @default.
- W2898108227 hasConceptScore W2898108227C126322002 @default.
- W2898108227 hasConceptScore W2898108227C141071460 @default.
- W2898108227 hasConceptScore W2898108227C143998085 @default.
- W2898108227 hasConceptScore W2898108227C2776256026 @default.
- W2898108227 hasConceptScore W2898108227C2776694085 @default.
- W2898108227 hasConceptScore W2898108227C2777240266 @default.
- W2898108227 hasConceptScore W2898108227C2777802072 @default.
- W2898108227 hasConceptScore W2898108227C2778239845 @default.
- W2898108227 hasConceptScore W2898108227C2908647359 @default.
- W2898108227 hasConceptScore W2898108227C61511704 @default.
- W2898108227 hasConceptScore W2898108227C71924100 @default.
- W2898108227 hasConceptScore W2898108227C90924648 @default.
- W2898108227 hasConceptScore W2898108227C99454951 @default.
- W2898108227 hasIssue "10" @default.
- W2898108227 hasLocation W28981082271 @default.
- W2898108227 hasOpenAccess W2898108227 @default.
- W2898108227 hasPrimaryLocation W28981082271 @default.
- W2898108227 hasRelatedWork W2008545061 @default.
- W2898108227 hasRelatedWork W2013563962 @default.
- W2898108227 hasRelatedWork W2069435948 @default.
- W2898108227 hasRelatedWork W2358450743 @default.
- W2898108227 hasRelatedWork W2774698410 @default.
- W2898108227 hasRelatedWork W3029430426 @default.
- W2898108227 hasRelatedWork W3031353651 @default.
- W2898108227 hasRelatedWork W3201348732 @default.
- W2898108227 hasRelatedWork W4256013750 @default.
- W2898108227 hasRelatedWork W49755809 @default.
- W2898108227 hasVolume "13" @default.
- W2898108227 isParatext "false" @default.
- W2898108227 isRetracted "false" @default.
- W2898108227 magId "2898108227" @default.
- W2898108227 workType "article" @default.